Go Pro
→ Your withdrawal order could cost you in taxes (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$3.85
+0.8%		$3.89
$1.30
▼
$4.85
$181.01M0.58273,671 shs121,891 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$11.85
-0.3%		$12.24
$11.00
▼
$13.10
$49.39M0.04904 shs1,225 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.97
-3.9%		$0.99
$0.86
▼
$1.63
$205.28M1.081.00 million shs815,139 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.48
+3.3%		$2.35
$1.52
▼
$3.19
$199.82M0.02931,696 shs1.02 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-2.05%-5.68%+19.38%-4.50%+62.55%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
-0.46%-0.08%-1.50%-1.01%+7.47%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
+1.00%+2.07%+11.28%-2.88%-12.93%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-0.41%+2.56%+1.27%+13.21%+50.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$3.85
+0.8%		$3.89
$1.30
▼
$4.85
$181.01M0.58273,671 shs121,891 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$11.85
-0.3%		$12.24
$11.00
▼
$13.10
$49.39M0.04904 shs1,225 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.97
-3.9%		$0.99
$0.86
▼
$1.63
$205.28M1.081.00 million shs815,139 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.48
+3.3%		$2.35
$1.52
▼
$3.19
$199.82M0.02931,696 shs1.02 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-2.05%-5.68%+19.38%-4.50%+62.55%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
-0.46%-0.08%-1.50%-1.01%+7.47%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
+1.00%+2.07%+11.28%-2.88%-12.93%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-0.41%+2.56%+1.27%+13.21%+50.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
2.67
Moderate Buy$10.00159.74% Upside
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
1.00
SellN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19331.39% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$12.00383.87% Upside

Current Analyst Ratings Breakdown

Latest BKHA, LUCD, ADAG, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/17/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.50
8/4/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/20/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/14/2026
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
6/8/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$9.00 ➝ $9.25
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$7.67M23.79N/AN/A$1.89 per share2.04
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$4.71M41.89N/AN/A$0.05 per share19.41
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$80.62M2.48$0.14 per share17.80$0.47 per share5.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$17.61MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.47N/AN/AN/A-959.76%N/A-119.57%11/11/2026 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.23N/A8.00N/A-21.03%-30.89%-11.74%N/A

Latest BKHA, LUCD, ADAG, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q2 2026
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$0.22N/AN/AN/A$17.50 millionN/A
8/13/2026Q2 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.0567-$0.06-$0.0033-$0.08$1.43 million$1.47 million
7/15/2026Q2 2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A$0.02N/A$0.02N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
N/AN/AN/AN/AN/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.01
5.02
3.07
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.33
1.31
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9.51%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
21.20%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
26047.39 million37.34 millionNot Optionable
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A4.15 millionN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
70203.24 million189.22 millionNo Data
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20080.57 million69.00 millionOptionable

Recent News About These Companies

Zacks Research Brokers Reduce Earnings Estimates for PLX
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975252
Zacks Research Issues Pessimistic Outlook for PLX Earnings
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zacks-research-issues-pessimistic-outlook-for-plx-earnings-2026-08-20/
Protalix (PLX) Q2 2026 Earnings Call Transcript
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/protalix-plx-q2-2026-earnings-142833654.html
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs
August 16, 2026  |  kalkinemedia.comK
PLX: Elfabrio estimates up
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/plx-elfabrio-estimates-up/ar-AA2a3iaX
Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4631765-protalix-signals-elfabrio-path-to-15-percent-to-20-percent-fabry-market-share-by-2031-backed
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935453-protalix-biotherapeutics-inc-plx-q2-2026-earnings-call-transcript
Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69289916-protalix-biotherapeutics-inc-protalix-biotherapeutics-reports-second-quarter-2026-financial-and-business-results-008.htm
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
August 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-second-quarter-2026-financial-and-business-results-302849539.html
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
August 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2026-financial-results-and-business-update-on-august-12-2026-302843662.html
Protalix BioTherapeutics (NYSE:PLX) Shares Down 2.6% - Here's Why
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protalix-biotherapeutics-nyseplx-shares-down-26-heres-why-2026-07-30/
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
May 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/protalix-biotherapeutics-inc-q1-2026-003442858.html
PLX: Chiesi Milestone Received
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/plx-chiesi-milestone-received-165500361.html
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript
May 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/protalix-biotherapeutics-inc-amexplx-q1-2026-earnings-call-transcript-1762043/
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
May 14, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/transcript-protalix-biotherapeutics-q1-2026-121950605.html
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/protalix-biotherapeutics-inc-plx-q1-230245793.html
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903948-protalix-biotherapeutics-inc-plx-q1-2026-earnings-call-transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
May 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-first-quarter-2026-financial-and-business-results-302770790.html
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
May 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2026-financial-results-and-business-update-on-may-13-2026-302763976.html
Protalix: Elfabrio Struggles Against Oral Competition
April 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891005-protalix-elfabrio-struggles-against-oral-competition
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
March 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4885453-protalix-revenue-miss-overshadowed-by-milestone-backed-2026-guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adagene stock logo

Adagene NASDAQ:ADAG

$3.85 +0.03 (+0.79%)
As of 04:00 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Black Hawk Acquisition stock logo

Black Hawk Acquisition NASDAQ:BKHA

$11.85 -0.04 (-0.34%)
As of 03:07 PM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$0.97 -0.04 (-3.89%)
As of 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$2.48 +0.08 (+3.33%)
As of 04:00 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas